Neurology Central

Risdiplam: positive topline results reported in FIREFISH trial for spinal muscular atrophy


PTC Therapeutics (NJ, USA) has announced positive topline results from part II of the FIREFISH trial assessing the efficacy of risdiplam – an investigational oral mRNA splicing modifier – in infants with Type 1 spinal muscular atrophy (SMA). Risdiplam was reported to have met its primary endpoint of infants who are sitting without support after 12 months of treatment. The drug was also well tolerated and no treatment-related safety findings leading to withdrawal were observed.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.